Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s10157-016-1379-0 http://scihub22266oqcxt.onion/10.1007/s10157-016-1379-0 C5648735!5648735!28190113     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28190113&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Exp+Nephrol 2017 ; 21 (5): 858-65 Nephropedia Template TP {{tp|p=28190113|t=2017. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure |pdf=|usr=}}{{28190113}} gab.com Text Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure JO: Clin Exp Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28190113 #FOAvip Background: Tolvaptan, a vasopressin V2 receptor blocker, has a diuretic effect for patients with heart failure. However, there were a few data concerning the effects of tolvaptan in patients with chronic kidney disease (CKD). Methods: We retrospectively analyzed 21 patients with chronic heart failure and CKD. Tolvaptan was co-administered with other diuretics in-use, every day. We compared clinical parameters before and after the treatments with tolvaptan. Furthermore, we examined the correlations between baseline data and the change of body weight. Results: Tolvaptan decreased the body weight and increased the urine volume (p?=?0.001). The urine osmolality significantly decreased throughout the study period. Urinary Na/Cr ratio and FENa changed significantly after 4 h, and more remarkable after 8 h (p?=?0.003, both). Serum creatinine increased slightly after 1 week of treatment (p?=?0.012). The alteration of body weight within the study period correlated negatively with the baseline urine osmolality (r?=??0.479, p?=?0.038), the baseline urine volume (r?=??0.48, p?=?0.028), and the baseline inferior vena cava diameter (IVCD) (r?=??0.622, p?=?0.017). Hyponatremia was improved to the normal value, and the augmentations of the sodium concentration were negatively associated with the basal sodium levels (p?=?0.01, r?=??0.546). Conclusions: Tolvaptan is effective in increasing diuresis and improved hyponatremia, even in patients with CKD. The baseline urine osmolality, urine volume, and IVCD may be useful predictors for diuretic effects of tolvaptan. Twit Text FOAVip Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure ????Clin Exp Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=28190113 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28190113 #FOAvip English Wikipedia <ref>{{Cite pmid|28190113}}</ref> Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure #MMPMID28190113 Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S Clin Exp Nephrol 2017[]; 21 (5): 858-65 PMID28190113show ga Background: Tolvaptan, a vasopressin V2 receptor blocker, has a diuretic effect for patients with heart failure. However, there were a few data concerning the effects of tolvaptan in patients with chronic kidney disease (CKD). Methods: We retrospectively analyzed 21 patients with chronic heart failure and CKD. Tolvaptan was co-administered with other diuretics in-use, every day. We compared clinical parameters before and after the treatments with tolvaptan. Furthermore, we examined the correlations between baseline data and the change of body weight. Results: Tolvaptan decreased the body weight and increased the urine volume (p?=?0.001). The urine osmolality significantly decreased throughout the study period. Urinary Na/Cr ratio and FENa changed significantly after 4 h, and more remarkable after 8 h (p?=?0.003, both). Serum creatinine increased slightly after 1 week of treatment (p?=?0.012). The alteration of body weight within the study period correlated negatively with the baseline urine osmolality (r?=??0.479, p?=?0.038), the baseline urine volume (r?=??0.48, p?=?0.028), and the baseline inferior vena cava diameter (IVCD) (r?=??0.622, p?=?0.017). Hyponatremia was improved to the normal value, and the augmentations of the sodium concentration were negatively associated with the basal sodium levels (p?=?0.01, r?=??0.546). Conclusions: Tolvaptan is effective in increasing diuresis and improved hyponatremia, even in patients with CKD. The baseline urine osmolality, urine volume, and IVCD may be useful predictors for diuretic effects of tolvaptan. äEffects of tolvaptan in patients with chronic kidney disease and chron(epmc).pdf DeepDyve Pubget Overpricing